A recent study using the same PPARβ/δ agonist demonstrated that PPARβ/δ upregulates serum high-density lipoprotein (HDL) and HDL phospholipids in NAFLD mice, while this effect is not seen in Pparβ/δ-deficient mice [151]. This evidence concerns the gene PPARD and metabolic dysfunction-associated steatotic liver disease.